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Aims:Cyclic AMP inhibits vascular smoothmuscle cell (VSMC)proliferationwhich is important in the aetiology of
numerous vascular diseases. The anti-mitogenic properties of cAMP in VSMC are dependent on activation of
protein kinase A (PKA) and exchange protein activated by cAMP (EPAC), but the mechanisms are unclear.
Methods and results: Selective agonists of PKA and EPAC synergistically inhibited Egr1 expression, which was
essential for VSMC proliferation. Forskolin, adenosine, A2B receptor agonist BAY60-6583 and Cicaprost also
inhibited Egr1 expression in VSMC but not in endothelial cells. Inhibition of Egr1 by cAMP was independent of
cAMP response element binding protein (CREB) activity but dependent on inhibition of serum response element
(SRE) activity. SRF binding to the Egr1 promoterwas notmodulated by cAMP stimulation. However, Egr1 expres-
sion was dependent on the SRF co-factors Elk1 and 4 but independent of MAL. Inhibition of SRE-dependent Egr1
expression was due to synergistic inhibition of Rac1 activity by PKA and EPAC, resulting in rapid cytoskeleton re-
modelling and nuclear export of ERK1/2. This was associated with de-phosphorylation of the SRF co-factor Elk1.
Conclusion: cAMP inhibits VSMC proliferation by rapidly inhibiting Egr1 expression. This occurs, at least in part,
via inhibition of Rac1 activity leading to rapid actin-cytoskeleton remodelling, nuclear export of ERK1/2, impaired
Elk1-phosphorylation and inhibition of SRE activity. This identiﬁes one of the earliestmechanismsunderlying the
anti-mitogenic effects of cAMP in VSMC but not in endothelial cells, making it an attractive target for selective
inhibition of VSMC proliferation.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1.0. Introduction
Vascular smooth muscle cell (VSMC) proliferation contributes to-
wards the development of various vascular diseases characterised by
pathological intima formation, including atherosclerosis [1], transplant
vasculopathy and pulmonary hypertension. Increased VSMC prolifera-
tion also contributes towards neointima formation after balloon angio-
plasty with and without stenting and vein grafting, limiting long-term
success of clinical interventions designed to treat atherosclerosis.
A complete understanding of themechanisms regulatingVSMCprolifer-
ation is therefore essential for the development of new therapies.
In healthy vessels, VSMCs have extremely low rates of proliferation
but this is elevated by injury or insult to the vessel wall. Pathological
loss of quiescence is triggered by release of mitogens from platelets
and VSMCs that activate signalling pathways that stimulate expressionistol Royal Inﬁrmary, University
. This is an open access article underof cell-cycle genes. Inactivation of negative signals that normally repress
VSMC proliferation is also required. The second messenger cyclic aden-
osine 3′,5′-monophosphate (cAMP) is a well characterised inhibitor of
VSMC proliferation implicated in maintaining VSMC quiescence and
promoting healing after vessel injury [2–4]. Elevated cAMP inhibits
VSMC proliferation in vitro and in vivo after vascular injury, ultimately
leading to a reduction in intima formation [4]. Although this phenome-
non has been recognised for many years, the underlying mechanisms
have remained incompletely understood. Immediate events include ac-
tivation of PKAwhich for many years was believed to be responsible for
all cAMP-mediated effects. PKA inhibition reverses anti-mitogenic effect
in VSMCs [5] but selective activation of PKA does not inhibit VSMC pro-
liferation, implicating a second cAMP-sensitive pathway [5]. EPAC1 is a
cAMP-sensitive protein with intrinsic GEF activity that couples cAMP to
activation of members of the Ras-like family of GTPases, such as Rap1.
Using EPAC-selective cAMP-analogues, we demonstrated that PKA and
EPAC pathways act synergistically to repress VSMC proliferation [5].
However, the mechanisms underlying this synergy remained elusive.
cAMP blocks progression through the G1-phase of the cell-cycle, atthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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for S-phase entry (e.g. Skp2, Cyclin D, c-myc) but these are relatively
late events following cAMP elevation [4,6,7]. Although cAMP inhibits
ERK phosphorylation in VSMC, prompting speculation that this under-
lies the anti-mitogenic effects of cAMP, other studies show that cAMP-
anti-mitogenesis can be dissociated from ERK inhibition, implying the
involvement of alternative mechanisms [3].
We characterised the early transcriptomic response in VSMCs after
selective activation of PKA, EPAC or both to identify novel mechanisms
underlying their ability to synergistically inhibit VSMC proliferation.
We identiﬁed, for theﬁrst time, coordinated inhibition of the immediate
response gene Early growth response 1 (Egr1) by PKA and EPAC and
showed this to be essential for cell-cycle control. cAMP-mediated
repression of Egr1 expression resulted from inhibition of serum-
response element activity via a mechanism involving the rapid inhibi-
tion of Rac1-mediated actin-cytoskeleton remodelling, nuclear export
of ERK1/2 and de-phosphorylation of the SRF co-factor, Elk1. Further-
more, we provide evidence that this mechanism is cell-type speciﬁc,
accounting at least in part for the divergent effects of cAMP on VSMC
and Endothelial cell proliferation,
2. Methods
Detailed materials and methods are outlined in the supplement.
2.1. Smooth muscle cell culture and HUVEC and bromo-deoxyuridine
(BrdU) labelling
Male Sprague Dawley rats were killed by cervical dislocation in ac-
cordance with the Directive 2010/63/EU of the European Parliament.
Approval was granted by the University of Bristol ethical review
board. Medial tissue was carefully dissected from the thoracic aorta
and cut into 1 mm2 pieces for explant culture, essentially as described
previously [6]. Pooled donor HUVECs were purchased from Promocell
and cultured in Promocell endothelial cell culture media (C-22210)
with 2% FCS unless otherwise stated. Stimulations were performed in
5% foetal calf serum/DMEM unless otherwise stated. Proliferation was
measured by culture in the presence of 10 μMbromo-deoxyuridine. Fol-
lowing ﬁxation in 70% ethanol, incorporated bromo-deoxyuridine was
detected by immune-histochemical staining as previously described [5].
2.2. Quantitative RT-PCR and western blotting
Quantiﬁcation of mRNA and protein levels was performed by
qRT-PCR and western blotting essentially as described previously [5].
2.3. Transfection and recombinant adenoviruses transduction
Plasmid transfection was performed by using nucleofection as
previously described [5].
2.4. Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed essentially as described previously [8].
3. Results
3.1. Selective activation of EPAC and PKA using selective cAMP-analogues
We used the cAMP analogues 8-CPT-2′-O-Me-cAMP (CPT) and N6-
Benzoyl-cAMP (BNZ) to selectively probe the biological function of
EPAC and PKA, respectively. Increasing concentrations of CPT dose-
dependently activated the EPAC-effector protein, Rap1 (Supplement
Fig. 1A). BNZ stimulation dose-dependently activated PKA (Supplement
Fig. 1B). Activation of both EPAC-Rap1 and PKA was detected after
30 min and persisted for at least 2 h (Supplement Fig. 1C). Importantly,CPT did not stimulate any detectable PKA activation or phosphorylation
of the PKA/PKG substrate VASP at any time-point, conﬁrming highly se-
lective EPAC activation. Likewise, BNZ did not stimulate EPAC-Rap1
signalling, conﬁrming selective PKA activation (Supplement Fig. 1C).
The effects are consistent with our previous observations [5].
3.2. Characterisation of EPAC and PKA-dependent transcriptomes in VSMC
We characterised the transcriptome of VSMC stimulated with EPAC
or PKA agonists to gain a mechanistic insight into the anti-mitogenic
action of cAMP. Stimulation with 200 μM of each agonist, alone or in
combination, for 8 h identiﬁed 86 signiﬁcantly regulated transcripts;
the twenty most changed are shown in Table 1. CPT stimulation alone
regulated only one gene compared to control (Zfp365; 1.28-fold
down-regulated), despite efﬁcient activation of EPAC-Rap1 signalling
in these cultures (Supplement Fig. 2). Gene ontology analysis of all 86
genes identiﬁed functions associated with ERK1/2 signalling, signal
transduction and cardiovascular disease (Supplement Table 3).
Validation of selected genes by qRT-PCR conﬁrmed the array data
(Supplement Fig. 3) and identiﬁed an additional small but signiﬁcant
inhibition of EGR1 and CNKSR3 in response to CPT. Furthermore,
CPT signiﬁcantly ampliﬁed the BNZ-dependent suppression of
Egr1 expression.
3.3. PKA and EPAC synergise to inhibit Egr1 expression
Based on the transcriptomic and qRT-PCR data, we focussed on Egr1,
given its role in cell-cycle regulation [9] and neointima formation [10].
Time course analysis demonstrated transient inhibition of Egr1 mRNA
by BNZ from 2 to 8 h, returning to control levels after 18 h (Fig. 1A).
Importantly, CPT signiﬁcantly deepened Egr1 mRNA inhibition by BNZ.
In this experiment, CPT had no signiﬁcant effect on Egr1mRNA, demon-
strating a synergistic action of PKA and EPAC pathways. To further
conﬁrm a role of EPAC, cells were infectedwith recombinant adenovirus
expressing constitutively active EPAC (Ad:active-EPAC) [5]. BNZ stimu-
lation of Ad:active-EPAC infected cells resulted in a signiﬁcantly greater
inhibition of Egr1 mRNA levels compared to Ad:Control infected cells
(Supplement Fig. 4). Stimulation of uninfected cells with neither BNZ
nor CPT alone for either 4 or 8 h signiﬁcantly reduced Egr1 protein levels
(Fig. 1B). However, co-stimulation with BNZ plus CPT for 8 h
dramatically reduced Egr1 protein to levels signiﬁcantly lower than
BNZ alone, further demonstrating synergistic inhibition of Egr1 by PKA
and EPAC.
3.4. Species and cell-type dependent inhibition of Egr1 expression by cAMP
The adenylate–cyclase activator, Forskolin, which activated both
PKA and EPAC pathways (Supplement Fig. 1C), rapidly inhibited
Egr1 mRNA and Egr1 protein levels after 8 h (Fig. 1C) in cells
cultured continuously in the presence of 5% serum mitogens. This
effect occurred in rat (Fig. 1C) or human aortic VSMC (Fig. 1D).
Furthermore, stimulation with Forskolin or BNZ plus CPT inhibited
PDGFBB stimulated Egr1 mRNA and protein expression in rat VSMC
(Supplement Fig. 5). Forskolin stimulation did not however inhibit
Egr1 mRNA or protein expression in human umbilical vein endothelial
cells (HUVEC) cultured asynchronously in 5% serum mitogens (Fig. 1E).
Forskolin stimulation signiﬁcantly stimulated Egr1 mRNA levels in
serum-starved HUVEC and signiﬁcantly enhanced VEGF-A stimulated
Egr1 mRNA (Supplement Fig. 6) indicating that cAMP-mediated inhibi-
tion of Egr1 is cell-type speciﬁc. Co-incubation of VSMC with a pharma-
cological PKA inhibitor completely prevented Forskolin-mediated
inhibition of Egr1 (Fig. 1F), consistent with an essential role of PKA.
Furthermore, siRNA-mediated silencing of EPAC (Fig. 1G) also
prevented the Forskolin inhibitor of Egr1 (Fig. 1H), consistent with
a role of EPAC.
Table 1
List of highest and lowest regulated genes (fold change) following stimulation with BNZ, CPT or both in combination for 8 h. Venn diagram shows distribution of all 86 signiﬁcantly
regulated genes.
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PKA and EPAC
Vasoactive agents, including adenosine and prostacyclin mediate
cAMP production and inhibition of VSMC proliferation by activation of
G-protein coupled receptors (GPCRs). To test if activation of these
GPCRs inhibits Egr1 expressionwe stimulated VSMC either with adeno-
sine, the speciﬁc adenosine A2B-receptor agonist BAY60-6583 or the
prostacyclin mimetic, Cicaprost. These agonists increased phosphoryla-
tion of the PKA substrate VASP and activated the EPAC effector, Rap1
(Supplement Fig. 7), conﬁrming activation of both pathways. Adenosine
and BAY60-6583 signiﬁcantly inhibited Egr1mRNA levels after 2 and 4 h
(Fig. 2A) and strongly inhibited Egr1 protein levels after 8 h (Fig. 2A
inset). Cicaprost stimulation also transiently inhibited Egr1 mRNA ex-
pression after 2 h, returning to control levels after 4 h (Fig. 2B), although
Egr1 protein levels were still reduced after 8 h. The PKA inhibitor
Rp-cAMPS signiﬁcantly attenuated BAY60-6583 (Fig. 2C) and Cicaprost
(Fig. 2D)mediated inhibition of Egr1. EPAC silencing also rendered cells
insensitive to BAY60-6583 or Cicaprost-mediated inhibition of Egr1
expression (Fig. 2E).
3.6. Egr1 is required for VSMC proliferation and its inhibition contributes
towards cAMP-induced growth arrest
Egr1 is essential for proliferation in many but not all [11] cell types.
To test if Egr1 inhibition contributes to VSMC proliferation we used
overexpression of a dominant-negative (DN) Egr1 or NAB2, an Egr1
repressor, to inhibit Egr1 transcriptional activity (Supplement Fig. 8).
DN-Egr1 and NAB2 expression both signiﬁcantly inhibited VSMC prolif-
eration (Fig. 3A, B, C), demonstrating a requirement for Egr1 activity for
efﬁcient cell-cycle progression in VSMC. To test the importance of Egr1
inhibition for the anti-mitogenic effects of cAMPwe quantiﬁed the abil-
ity of Forskolin to inhibit proliferation in cells lacking Egr1 activity
(achieved via NAB2 overexpression). Forskolin stimulation inhibitedproliferation in control adenovirus infected cells (Fig. 3C). Infection
with Ad:NAB2 also signiﬁcantly inhibited proliferation (Fig. 3B, C).
However, Forskolin no longer signiﬁcantly inhibited VSMC proliferation
in NAB2 overexpressing cells compared to untreated NAB2 overex-
pressing cells (Fig. 3C), which lack Egr1 activity (Supplement Fig. 8).
Proliferation in Ad:Control plus Forskolin and Ad:NAB2 plus Forskolin
cells was not signiﬁcantly different.
3.7. Elevation of cAMP inhibits Egr1 transcription
To test if cAMP reduces Egr1 mRNA levels by inhibiting Egr1 gene
transcription we quantiﬁed Egr1 hnRNA (pre-spliced RNA), a surrogate
measure of transcriptional rate, as previously described [12], and activ-
ity of a−600 bp Egr1 promoter luciferase reporter (Egr1-luc). Forskolin
treatment potently inhibited levels of Egr1 hnRNA within 1 h, with
maximal inhibition after 4 h (Fig. 4A) and also signiﬁcantly inhibited
Egr1-luc promoter activity after 4 and 8 h (Fig. 4B). Inhibition of Egr1-
luc reporter activity was slower than endogenous hnRNA presumably
due to inherent differences in turnover rates of luciferase and Egr1 pro-
tein and mRNA. To test if PKA and EPAC cooperate to inhibit Egr1 tran-
scription, cells were stimulatedwith BNZ, CPT or BNZ plus CPT (Fig. 4C).
BNZ or CPT stimulation alone resulted in modest but signiﬁcant inhibi-
tion of Egr1 promoter activity that was enhanced by co-stimulation
with BNZ and CPT to levels that were signiﬁcantly less than BNZ or
CPT alone. Taken together, this data demonstrates that cAMP mediates
inhibition of Egr1 gene transcription in VSMC through PKA and EPAC.
3.8. Elevation of cAMP inhibits Egr1 expression via a CREB-independent but
SRF-dependent pathway
The proximal Egr1 promoter contains two binding elements for
CREB. CREB activation by cAMP has been linked to regulation of gene
transcription implicated in inhibition of VSMC proliferation [13]. We
therefore tested if CREB activation underlies the cAMP-mediated
Fig. 1. cAMP-elevating stimuli inhibit Egr1 expression via PKA and Epac in VSMC but not EC. VSMCs were stimulated with 200 μM BNZ, CPT or both for times indicated. Egr1 mRNA was
quantiﬁed by qRT-PCR (A) and protein by western blotting (B). Rat (C) or Human (D) aortic VSMC or HUVEC (E) were stimulated with 25 μM Forskolin for the indicated times and Egr1
mRNA and protein was measured by qRT-PCR (graphs) and western blotting (inset). Cells pre-treated with 10 μMH89 for 10 min were stimulated with Forskolin for 2 h (F). Cells were
transfectedwith control or EPAC-targeting siRNAand EPACmRNA andprotein analysed after 48 h (G) or cells stimulatedwith Forskolin for 2 h and Egr1mRNAquantiﬁed (H). * indicates
p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001 relative to control. # symbols indicate the same p values but versus BNZ alone samples.
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reporter gene activity, consistent with CREB activation (Fig. 5A)
which was completely blocked by adenovirus-mediated expression
of dominant-negative A-CREB (Ad:A-CREB) (Fig. 5B). Ad:A-CREB infec-
tion also completely blocked BNZ stimulated expression of classical
CREB-dependent genes, CREM and HAS (Fig. 5C), conﬁrming efﬁcient
inhibition of CREB activity. Importantly, Ad:A-CREB had no effect on
BNZ-mediated inhibition of Egr1 mRNA expression (Fig. 5D), indicating
that this operates via a CREB-independent mechanism.
The Egr1 promoter also contains multiple serum response elements
(SREs) that bind serum response factor (SRF) and members of the
Ternary Complex Factor (TCF) family, including Elk1 that function as
SRF co-factors. Given the central role of SRF and its co-factors in control-
ling proliferation, we asked if modulation of SRE activity could explaincAMP-mediated inhibition of Egr1 expression in VSMC. Consistent
with this, Forskolin inhibited SRE-dependent reporter activity 4 and 8
h after stimulation (Fig. 5E). CPT stimulation did not affect SRE-luc
activity, whereas BNZ resulted in a small but signiﬁcant inhibition
(Fig. 5F). Furthermore, BNZ inhibition of SRE-luc activitywas further en-
hanced by co-stimulation with CPT (Fig. 5F). This data indicates that
cAMP mediates suppression of Egr1 expression via PKA and EPAC
inhibition of SRE activity. Consistent with this, Egr1 promoter activity
was inhibited by truncation of the distal SRE elements and abolished
by mutation of the proximal pair of SREs (Fig. 5G). We next asked if
cAMP-mediated inhibition of Egr1 was mediated by reduced SRF bind-
ing to the Egr1 promoter. Surprisingly, despite signiﬁcant inhibition of
SRE-dependent transcriptional activity, Forskolin stimulation had no
effect on SRF binding, measured by ChIP, to either the proximal or distal
Fig. 2. Inhibition of Egr1 expression by Adenosine, BAY60-6582 and Cicaprost via PKA andEPAC. Rat VSMC stimulatedwith 100 μMadenosine or 1 μg/ml BAY-60-6583 (A, C and E) or 1 μM
Cicaprost (B,D and E) for indicated times were analysed for Egr1 mRNA and protein expression qRT-PCR (graphs) and western blotting (insets). Where indicated, cells were pre-treated
with 200 μM Rp-cAMPS (C and D) or transfected with siRNA targeting EPAC (E). * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
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for SRF in cAMP-mediated inhibition of Egr1, we attempted to rescue
Egr1 expression by expressing constitutively-active SRF (SRF-VP16). In
control vector transfected cells, Forskolin signiﬁcantly inhibited Egr1
expression (Fig. 5I). Importantly, SRF-VP16 expression signiﬁcantly
elevated basal Egr1 mRNA levels and completely prevented Forskolin-
mediated inhibition (Fig. 5I).
3.9. Elevation of cAMP suppresses Egr1 via inhibition of Rac1 and disruption
of the actin-cytoskeleton
cAMP-mediated growth arrest in VSMC is associated with a
dramatic change in cell morphology, characterised by a condensed
cell body with extended membrane processes (often referred to as
stellate morphology) together with loss of F-actin stress ﬁbres [14].
Since PKA and EPAC synergise to induce these morphological and cyto-
skeletal changes [15], and actin-cytoskeleton remodelling has been
implicated in the regulation of SRE activity [16], we asked if this mech-
anism underlies Egr1 inhibition. Consistent with our previous observa-
tions [15], CPT plus BNZ stimulation, but not BNZ or CPT alone, strongly
induced stellate morphology and F-actin loss (data not shown). Impor-
tantly, stellate morphology is evident within 20 min in response to a
range of cAMP-elevating stimuli (Supplement Fig. 9), preceding inhibi-
tion of Egr1 expression. Disruption of actin polymerisation with eithercytochalasin-D or latrunculin-B potently inhibited Egr1 mRNA expres-
sion (Fig. 6A), consistent with actin-dependent regulation of Egr1.
However, it is interesting to note that in endothelial cells, cAMP stimu-
lation does not cause a loss of F-actin stress ﬁbres (Supplement Fig. 10)
and does not inhibit Egr1 expression (Fig. 1E and Supplement Fig. 6),
consistent with a role of actin-remodelling in the cAMP-dependent
regulation of Egr1.
RhoA and Rac1 GTPases have been implicated in cAMP-mediated
actin-cytoskeleton remodelling, morphological changes and mitogenic
responses in VSMC [14,17]. Forskolin stimulation potently suppressed
RhoA activity in VSMC (Fig. 6B) and inhibition of RhoA or its effector
ROCK using C3 transferase or Y27632 respectively, mimicked cAMP-
induced morphological changes (Fig. 6C). However, RhoA or ROCK
inhibition did not signiﬁcantly affect Egr1 mRNA expression (Fig. 6D).
Furthermore, expression of a constitutively-active mutant of RhoA
(RhoA G14V) (Supplement Fig. 11A) did not rescue Egr1 mRNA
(Fig. 6E) or protein (Fig. 6F) expression after Forskolin stimulation,
despite a partial reversal of stellate morphology (Supplement Fig. 11C).
Together, this data implies RhoA-independent regulation of Egr1 by
cAMP. We therefore investigated the role of Rac1. CPT plus BNZ
or Forskolin stimulation, but not CPT or BNZ alone, signiﬁcantly
inhibited Rac1 activity (Fig. 6G). Importantly, adenovirus-mediated
expression of a constitutively-active mutant of Rac1 (Rac1-G12V)
(Supplement Fig. 11B) prevented Forskolin-induced stellatemorphology
Fig. 3. Inhibition of Egr1 contributes toward cAMP anti-mitogenesis. BrDU incorporation
was quantiﬁed 42 h after inhibition of Egr1 activity by transfection with dominant-
negative Egr1 (A) or adenovirus encoding the Egr1 repressor NAB2 (B). Cells infected
with either control or NAB2 adenovirus were stimulated with 25 μM Forskolin for 16 h
followed by 4-h incubation with BrDU (C). Data is mean fold regulation ± SEM
from at least three experiments. *** indicates p b 0.001, ** indicates p b 0.01, * indicates
p b 0.05; ANOVA with Student–Newman–Keuls post-test.
Fig. 4. cAMP inhibits Egr1 gene transcription. VSMCwere stimulatedwith 25 μMForskolin
for indicated times. Egr1 pre-spliced hnRNA quantiﬁed by qRT-PCR, n = 4 (A) Effect on
Egr1-luc reporter (n = 5) gene activity was quantiﬁed after stimulation with 25 μM
Forskolin (B) or 200 μM BNZ and/or CPT for 4 h (C). * indicates p b 0.05, ** indicates
p b 0.01, *** indicates p b 0.001 vs Control; # indicates p b 0.05 vs BNZ by ANOVA.
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in SRE-luc (Fig. 6H) and signiﬁcantly attenuated the Forskolin-
mediated inhibition of Egr1 mRNA (Fig. 6I) and protein (Fig. 6J).
3.10. cAMP represses Egr1 expression via an Elk-dependent but MAL
independent mechanism
Inhibition of Rac1 activity, impaired actin polymerisation and the
resulting increase in actin monomer have all been linked to inhibition
of SRE activity in other cell types [18]. This occurs, in part, via cytoplas-
mic sequestration of the SRF co-factor MAL (MAL/MKL1/MRTF-A) by
monomeric-actin. Consistent with this, elevation of monomeric-actin,
via expression of a non-polymerisable actin-mutant (Actin-R62D), po-
tently and signiﬁcantly inhibited SRE-luc activity (Fig. 7A). Actin-R62D
also inhibited Egr1 mRNA (Fig. 7B). We therefore asked if cAMP-
elevation inhibits Egr1 expression by sequestering MAL in the cyto-
plasm. GFP-MAL was localised exclusively in the cytoplasm in
serum-starved cells but translocated to the nucleus within 1 h in re-
sponse to serum stimulation (Fig. 7C). Forskolin stimulation blocked
serum-induced nuclear localisation of MAL, consistent with cAMP inhi-
bition of MAL-SRF signalling. However, siRNA-mediated silencing of
MAL did not affect Egr1 mRNA expression (Fig. 7D), implying that
cAMP-dependent regulation of Egr1 is independent of the MAL-SRF
pathway. We therefore investigated the role of the other SRF cofactors,Elk1 and Elk4. Silencing of Elk1 or Elk4 alone had no effect on Egr1
mRNA expression (data not shown) whereas simultaneous silencing
of both potently inhibited Egr1 mRNA expression (Fig. 7E). This is
consistent with previously reported functional redundancy between
these co-factors [19]. Forced expression of constitutively-active Elk1
(Elk1-VP16) resulted in a partial but signiﬁcant reversal of Forskolin-
inhibited Egr1 expression (Fig. 7F). Taken together, this data demon-
strates a role for Elk in the cAMP-dependent regulation of Egr1 in
VSMC. To gain an insight into the underlying mechanismwe measured
changes in Elk1 binding to the Egr1 promoter and Elk-phosphorylation
Fig. 5. cAMP inhibition of Egr1 expression is CREB-independent but SRE-dependent. CRE-Luc transfected VSMC were infected with either Ad:Control or Ad:A-CREB (dominant-negative
CREB). Cells were stimulatedwith 200 μMBNZ and luciferase activity, (A and B) ormRNA expression of CREM and HAS (C) or Egr1 (D) quantiﬁed after 4 h for luciferase or 8 h for mRNA.
Luciferase activitywas quantiﬁed in cells transfectedwith SRE-luc and stimulatedwith 25 μM forskolin (E) or 200 μMBNZ, CPT or both for 4 h (F). Luciferase activity was quantiﬁed in cells
transfected with either−600 Egr1-luc, -141 Egr1-luc of−141 double SREmutated Egr1-luc (G). SRF binding to the proximal and distal SRE clusters in the Egr1 promoter was quantiﬁed
byChIP (H). Proximal Skp2promoterwasused as a non-SRE control. VSMCwere transfectedwith SRF-VP16 and stimulatedwith Forskolin for 90min24h post-transfection (I) Egr1mRNA
was quantiﬁed by qRT-PCR. * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001, # indicates p b 0.05 vs BNZ alone.
15T.E. Kimura et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 9–19in response to cAMP-elevation. ChiP analysis detected basal binding of
Elk1 to the proximal and distal Egr1 promoter but thiswas notmodulat-
ed by Forskolin stimulation (Fig. 7H). However, Forskolin stimulation
rapidly resulted in a loss of Elk1-phosphorylation (Fig. 7I). Since Elk1
is an ERK1/2 substrate and cAMP inhibits ERK1/2 activity in VSMC [2],
we investigated the role of ERK1/2 in cAMP-dependent Egr1 regulation.
ERK1/2 inhibition with PD98059 potently repressed Egr1 mRNA ex-
pression to similar levels achieved by forskolin (Fig. 7J). However,
cAMP stimulation inhibited Egr1 mRNA expression as early as 60 min(Fig. 7K) but did not inhibit ERK1/2 phosphorylation at this time-
point (Fig. 7L). Although Egr1 expression is ERK1/2 dependent, its
inhibition by cAMP preceded the loss of ERK1/2 phosphorylation,
implicating an alternative cAMP-regulated mechanism. Interestingly,
cAMP-elevation rapidly (within 20 min) blocked mitogen-stimulated
nuclear localisation of ERK1/2 (Fig. 7M). Actin-cytoskeleton disruption
with cytochalasin-D also blocked ERK1/2 nuclear localisation, consis-
tent with our observed effects of cAMP on cytoskeleton remodelling
in these cells (Fig. 7M).
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Elevated levels of cAMP potently inhibit VSMC proliferation by
inhibiting expression of multiple G1 cell-cycle proteins, including
Cyclin-D1, Skp2 and c-myc [4]. However, the early upstream signalling
mechanisms are incompletely characterised. For many years, PKA was
thought to be solely responsible for the action of cAMP. However, we re-
cently demonstrated that selective PKA activation is insufﬁcient to in-
hibit VSMC proliferation, implicating the involvement of a second
cAMP-sensitive pathway, which we identiﬁed as EPAC [5]. EPAC is a
cAMP-sensitive proteinwith GEF activity coupling cAMP levels to down-
streameffectors, such as Rap1. PKA and EPAC pathways act synergistical-
ly to repress VSMCproliferation [5]. However, themechanisms remained
elusive. In this study, we demonstrate that PKA and EPAC synergistically
inhibit expression of Egr1, whichwe show is an essential factor initiating
cell-cycle progression [20]. Our data indicates that suppression of Egr1
occurs in response to inhibition of Rac1-dependent cytoskeleton-
remodelling, which triggers rapid nuclear export of ERK1/2 and de-
phosphorylation of Elk1. This represents one of the earliest mechanisms
underlying the anti-mitogenic effects of cAMP in VSMC.Egr1 is a zinc-ﬁnger transcription factor that is rapidly and transient-
ly induced in many different cell types, including VSMC, in response to
growth factors, cytokines and tissue injury [21]. Increased Egr1 expres-
sion is found in various vascular pathophysiological processes associat-
ed with increased vascular cell proliferation, including atherosclerosis,
restenosis [22], diabetes [23], hypoxia induced pulmonary hypertension
[24] and ischemia induced arteriogenesis [25] where it is associated
with elevated expression of multiple Egr1 target genes involved in the
proliferative response [26]. Interventions to block Egr1 expression or
function, including antisense ODNs [27], decoy ODNs [28], DNAzymes
[20], and siRNA [29] effectively inhibit VSMC proliferation in vitro and
in vivo, ultimately reducing neointimal lesion formation, identifying
Egr1 as a potential therapeutic target. Our data showing that inhibition
of Egr1 activity effectively blocks VSMC proliferation conﬁrms the es-
sential role for Egr1 in controlling G1-S phase progression in VSMC.
Our data also demonstrates for the ﬁrst time that cAMP rapidly and po-
tently inhibits Egr1 expression in VSMC and that cAMP induced growth
arrest is attenuated in cells lacking Egr1 activity. We therefore suggest
that this represents one of the earliest mechanisms underlying the
anti-mitogenic effects of cAMP in these cells. We provide evidence
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such as prostacylin and extracellular adenosine that are known to play
a role in maintaining a quiescent VSMC phenotype and restraining pro-
liferation after injury by stimulating cAMP synthesis, suggesting that it
may play a role in regulating vascular homeostasis. It is interesting to
note that Egr1 is also a critical positive regulator of endothelial cell pro-
liferation [30]. However, our data demonstrates that cAMP-dependent
inhibition of Egr1 expression is cell-type speciﬁc, occurring in VSMC
but not in endothelial cells, where cAMP actually stimulates Egr1
expression. This raises the possibility that these properties might be
exploited pharmacologically to speciﬁcally inhibit VSMC proliferation
to combat restenosis.
We show that the early down-regulation of Egr1 expression by
cAMP elevation in VSMC is largely due to transcriptional inhibition.
Although the Egr1 promoter contains two conserved CREB binding ele-
ments our data shows that its inhibition by cAMP is CREB-independent.
This is consistent with previous studies showing that CREB positively
regulates Egr1 transcription in VSMC [31] and pancreatic β-cells [32]
in response to other stimuli. Instead, our data implicates the SRE ele-
ments in the Egr1 promoter as the target for repression by cAMP. Egr1transcription is dependent on these SRE elements and cAMP signalling,
via PKA and EPAC, inhibits SRE-dependent transcriptional activity.
Furthermore, expression of constitutively-active SRF rescues Egr1 ex-
pression after cAMP-stimulation, consistent with SRE being the target
for cAMP-mediated repression. Interestingly, this is not associated
with loss of binding of SRF to these elements. Instead our data demon-
strates that inhibition of SRE activity and Egr1 expression is triggered
by actin-cytoskeleton remodelling induced by cAMP. Elevated cAMP
induces profound and rapid morphological changes due to disruption
of actin stress ﬁbres in VSMC [5,14] but not in endothelial cells where
we show that cAMP does not inhibit Egr1. cAMP, via the synergistic ac-
tion of PKA and EPAC, induces this cytoskeleton reorganisation by
inhibiting RhoA and Rac1 GTPases [14,17]. However, our data demon-
strates that although inhibition of the RhoA/ROCK pathway mimicked
cAMP-induced morphological changes and this was at least partially
reversed by constitutively-active RhoA, neither affected Egr1 expres-
sion. Hence Rac1, rather than RhoA, is the primary mediator of
cAMP-dependent inhibition of Egr1 expression in VSMC. This is consis-
tent with previous work demonstrating distinct functional roles of these
GTPases on gene expression [33] and an essential role for Rac1 for VSMC
18 T.E. Kimura et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 9–19proliferation and intima formation in vivo [14]. We demonstrate that
expression of constitutively-active Rac1 rescues SRE-activity and
Egr1 expression after cAMP-stimulation, consistent with previous
work linking Rac1 activity to SRF-dependent gene expression in
ﬁbroblasts [34].
Increased levels of monomeric-actin, resulting from impaired actin
polymerisation, have been implicated in mediating SRF inhibition and,
as we now show, also inhibit Egr1 expression in VSMC. One previously
described mechanism is via cytoplasmic sequestration of the SRF co-
factor MAL [16] and we show, for the ﬁrst time, that cAMP-mediated
actin-remodelling regulates nuclear localisation of MAL in VSMC,
which could be functionally important. However, siRNA-silencing of
MAL clearly demonstrated that Egr1 is not aMAL target in VSMC, impli-
cating alternativemechanisms. Instead our data demonstrates that Egr1
expression is absolutely dependent on the SRF co-factors Elk1 and Elk4.
cAMP stimulation inhibits Elk1 phosphorylation and cAMP-mediated
inhibition of Egr1 reversed in cells expressing constitutively-active
Elk1, strongly suggesting that Elk1, at least in part, is a target for
cAMP-mediated inhibition of SRE-activity and Egr1 expression in
VSMC. Given that Elk1 is an ERK1/2 target and cAMP is known to inhibit
ERK1/2 activity in VSMC it is likely that cAMP-mediated ERK1/2
inhibition is involved in Egr1 regulation. Our data demonstrates that
cAMP elevation rapidly (within 20 min) blocks nuclear targeting of
ERK1/2, preceding Egr1 inhibition, which implies that nuclear export
of ERK1/2 rather than inhibition of phosphorylation underlies the inhi-
bition of Elk1 phosphorylation and Egr1 expression. The fact that direct
cytoskeleton disruption with CytochalasinD also rapidly blocks ERK1/2
nuclear targeting strongly suggests that cAMP-induced cytoskeleton
remodelling is responsible for cAMPs' effects on ERK1/2 localisation,
Elk1-phosphoryaltion, Egr1 expression and ultimately growth arrest.
Why Egr1 expression is divergently regulated by cAMP in VSMC and
EC is currently unknown but clearly an important area of future
research. Our data points to the striking differences in cytoskeleton
remodelling in response to cAMP between these cell types. Whether
this reﬂects differences in the regulation of upstream Rho-family
GTPasess or the way the cytoskeleton organised in these cells is
currently unknown.5. Conclusions
In summary, we demonstrate that PKA and EPAC synergise to in-
hibit VSMC proliferation by rapidly inhibiting EGR1 expression. This
occurs, at least in part, via inhibition of Rac1 activity leading to rapid
actin-cytoskeleton remodelling, nuclear export of ERK1/2, impaired
Elk1-phosphorylation and inhibition of SRE activity (see supplement
Fig. 12). This likely represents one of the earliest mechanisms underly-
ing the anti-mitogenic effects of cAMP and highlights the previously un-
derappreciated importance of actin-cytoskeleton remodellingmediating
the biological effects of cAMP in VSMC. Importantly, this mechanism is
cell-type speciﬁc, operating in VSMC but not in EC and may have poten-
tial for the development of VSMC-speciﬁc anti-proliferative therapies for
the treatment of restenosis.Disclosures
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Glossary
BrdU: 5-Bromo-2-deoxyuridine
cAMP: 3′-5′-cyclic adenosine monophosphate
CREB: cAMP response element binding protein
Egr1: early growth response 1
EPAC: exchange protein activated by cAMP
ERK1/2: extracellular signal-regulated kinase 1 and 2
ODNs: oligodeoxynucleotide
PKA: protein kinase A
Rap1: Ras-related protein 1
SRE: serum response element
SRF: serum response factor
VSMC: vascular smooth muscle cell
Elk: E26-like kinase 1
Rho: ras homolog family member A
Rac: ras-related C3 botulinum toxin substrate 1
